RT Journal Article
T1 The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
A1 Forero-Castro, Maribel
A1 Robledo, Cristina
A1 Lumbreras, Eva
A1 Benito, Rocio
A1 Hernández-Sánchez, Jesús M
A1 Hernández-Sánchez, María
A1 García, Juan L
A1 Corchete-Sánchez, Luis A
A1 Tormo, Mar
A1 Barba, Pere
A1 Menárguez, Javier
A1 Ribera, Jordi
A1 Grande, Carlos
A1 Escoda, Lourdes
A1 Olivier, Carmen
A1 Carrillo, Estrella
A1 García de Coca, Alfonso
A1 Ribera, Josep-María
A1 Hernández-Rivas, Jesús M
K1 Burkitt lymphoma
K1 array-based comparative genomic hybridization (aCGH)
K1 next-generation sequencing
K1 outcome
K1 rituximab
AB The introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients have not been explored. This study aimed to identify the presence of genomic changes that could predict the response to new therapies in BL. Forty adolescent and adult BL patients treated with the Dose-Intensive Chemotherapy Including Rituximab (Burkimab) protocol (Spanish Programme for the Study and Treatment of Haematological Malignancies; PETHEMA) were analysed using array-based comparative genomic hybridization (CGH). In addition, the presence of TP53, TCF3 (E2A), ID3 and GNA13 mutations was assessed by next-generation sequencing (NGS). Ninety-seven per cent of the patients harboured genomic imbalances. Losses on 11q, 13q, 15q or 17p were associated with a poor response to Burkimab therapy (P = 0·038), shorter progression-free survival (PFS; P = 0·007) and overall survival (OS; P = 0·009). The integrative analysis of array-CGH and NGS showed that 26·3% (5/19) and 36·8% (7/19) of patients carried alterations in the TP53 and TCF3 genes, respectively. TP53 alterations were associated with shorter PFS (P = 0·011) while TCF3 alterations were associated with shorter OS (P = 0·032). Genetic studies could be used for risk stratification of BL patients treated with the Burkimab protocol.
YR 2015
FD 2015-11-16
LK http://hdl.handle.net/10668/9621
UL http://hdl.handle.net/10668/9621
LA en
DS RISalud
RD Apr 7, 2025